ATE231916T1 - Intrazellulaere bindungs proteine und deren anwendungen - Google Patents

Intrazellulaere bindungs proteine und deren anwendungen

Info

Publication number
ATE231916T1
ATE231916T1 AT94919711T AT94919711T ATE231916T1 AT E231916 T1 ATE231916 T1 AT E231916T1 AT 94919711 T AT94919711 T AT 94919711T AT 94919711 T AT94919711 T AT 94919711T AT E231916 T1 ATE231916 T1 AT E231916T1
Authority
AT
Austria
Prior art keywords
pct
binding proteins
date dec
applications
intracellular binding
Prior art date
Application number
AT94919711T
Other languages
English (en)
Inventor
Fabien Schweighoffer
Bruno Tocque
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE231916T1 publication Critical patent/ATE231916T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/084—Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1147—Regulatory proteins, e.g. trans-activator of transcription [TAT], rev or vacuolar protein targeting [VPT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT94919711T 1993-06-16 1994-06-15 Intrazellulaere bindungs proteine und deren anwendungen ATE231916T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9307241A FR2706486B1 (fr) 1993-06-16 1993-06-16 Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques.
PCT/FR1994/000714 WO1994029446A2 (fr) 1993-06-16 1994-06-15 Proteines intracellulaires de liaison (pil) et leurs utilisations

Publications (1)

Publication Number Publication Date
ATE231916T1 true ATE231916T1 (de) 2003-02-15

Family

ID=9448183

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94919711T ATE231916T1 (de) 1993-06-16 1994-06-15 Intrazellulaere bindungs proteine und deren anwendungen

Country Status (24)

Country Link
US (1) US6159947A (de)
EP (1) EP0703980B1 (de)
JP (1) JP4384260B2 (de)
KR (1) KR100342233B1 (de)
CN (1) CN1076052C (de)
AT (1) ATE231916T1 (de)
AU (1) AU7076394A (de)
BR (1) BR9407512A (de)
CA (1) CA2165458C (de)
CZ (1) CZ289039B6 (de)
DE (1) DE69432075T2 (de)
DK (1) DK0703980T3 (de)
ES (1) ES2191031T3 (de)
FI (1) FI120311B (de)
FR (1) FR2706486B1 (de)
HU (1) HU219138B (de)
NO (1) NO319466B1 (de)
NZ (1) NZ268038A (de)
PL (1) PL180760B1 (de)
RU (1) RU2218400C2 (de)
SK (1) SK285169B6 (de)
UA (1) UA46709C2 (de)
WO (1) WO1994029446A2 (de)
ZA (1) ZA944303B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790633B1 (en) * 1990-04-18 2004-09-14 Michael S. Brown Method of inhibiting a farnesyl transferase enzyme
US8003342B1 (en) 1990-04-18 2011-08-23 Board Of Regents, The University Of Texas System Method for identifying farnesyl transferase inhibitors
FR2724320B1 (fr) * 1994-09-13 1996-12-20 Transgene Sa Nouvel implant pour le traitement des maladies acquises
US5518042A (en) * 1994-09-16 1996-05-21 Huyck Licensco, Inc. Papermaker's forming fabric with additional cross machine direction locator and fiber supporting yarns
FR2738151B1 (fr) * 1995-09-04 1997-09-26 Rhone Poulenc Rorer Sa Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers
US7008776B1 (en) * 1996-12-06 2006-03-07 Aventis Pharmaceuticals Inc. Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
US6395530B1 (en) 1996-12-06 2002-05-28 Aventis Pharmaceuticals Inc. LLG polypeptides of the triacylglycerol lipase family, and compositions and methods for their use in enzymatic hydrolysis, and protein and gene therapies
FR2758569B1 (fr) * 1997-01-20 1999-04-02 Centre Nat Rech Scient Materiel biologique pour le traitement d'un mammifere par transfert de gene d'anticorps et composition pharmaceutique le concernant
WO2000050089A2 (en) * 1999-02-26 2000-08-31 Mindset Biopharmaceuticals (Usa) Ltd. Regulation of the stability of recombinant proteins and antiboodies
FR2794771B1 (fr) 1999-06-11 2001-08-10 Aventis Pharma Sa Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
GB0018307D0 (en) 2000-07-26 2000-09-13 Aventis Pharm Prod Inc Polypeptides
PT1290023E (pt) 2000-03-31 2011-01-05 Aventis Pharma Inc Factor indutor do factor nuclear kb
US20030104402A1 (en) * 2001-01-23 2003-06-05 University Of Rochester Methods of producing or identifying intrabodies in eukaryotic cells
RU2317330C2 (ru) * 2006-01-16 2008-02-20 Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека" РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pcL37, КОДИРУЮЩАЯ ПОЛИПЕПТИД СО СВОЙСТВАМИ ЛЕГКОЙ ЦЕПИ АНТИТЕЛА ЧЕЛОВЕКА ПРОТИВ ВИРУСА ОСПОВАКЦИНЫ, РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pcH37, КОДИРУЮЩАЯ ПОЛИПЕПТИД СО СВОЙСТВАМИ ТЯЖЕЛОЙ ЦЕПИ УКАЗАННОГО АНТИТЕЛА, И ИХ ПРИМЕНЕНИЕ
WO2012162628A2 (en) 2011-05-25 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lipopeptide inhibitors of ras oncoproteins
KR101602876B1 (ko) * 2014-07-22 2016-03-11 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용
KR101602870B1 (ko) 2014-07-22 2016-03-21 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용
US20180072815A1 (en) 2014-10-23 2018-03-15 Singh Biotechnology, Llc Single Domain Antibodies Directed Against Intracellular Antigens
US20160115247A1 (en) * 2014-10-23 2016-04-28 Singh Biotechnology, Llc Single domain antibodies directed against intracellular antigens
TWI746473B (zh) 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 針對細胞內抗原之單域抗體
MX2018014554A (es) 2016-05-27 2019-09-09 Orum Therapeutics Inc Anticuerpo penetrante de citosol y uso del mismo.
US10787487B2 (en) 2018-06-21 2020-09-29 Orum Therapeutics Inc. Cell/tissue-specific cell-penetrating antibodies
CN110981943B (zh) * 2019-12-02 2021-08-03 清华大学 多肽及其在制备药物中的用途和药物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3915952A1 (de) * 1989-05-12 1990-12-06 Peter Werner Wirkstoff/medikament/biotechnologisches verfahren zur behandlung von erkrankungen, die mit exo- oder endogenen intrazellulaeren proteinen (onkogene etc.) assoziert sind
EP0556197A4 (en) * 1990-09-25 1994-05-18 Univ Connecticut Prolonging expression of polynucleotides introduced into a cell
CA2072249C (en) * 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
WO1993007286A1 (en) * 1991-09-30 1993-04-15 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Recombinant immunotoxins
EP0618970A1 (de) * 1991-12-10 1994-10-12 Dana Farber Cancer Institute Reaktive neutralisierende humane anti-gp120 rekombinante antikörper, entsprechend kodierende dna und ihre verwendung
AU687010B2 (en) * 1992-07-17 1998-02-19 Dana-Farber Cancer Institute Method of intracellular binding of target molecules

Also Published As

Publication number Publication date
SK156895A3 (en) 1996-05-08
SK285169B6 (sk) 2006-07-07
UA46709C2 (uk) 2002-06-17
CA2165458A1 (fr) 1994-12-22
US6159947A (en) 2000-12-12
NO955011D0 (no) 1995-12-11
JPH08511162A (ja) 1996-11-26
EP0703980B1 (de) 2003-01-29
RU2218400C2 (ru) 2003-12-10
DK0703980T3 (da) 2003-05-19
ZA944303B (en) 1995-02-14
HUT74266A (en) 1996-11-28
JP4384260B2 (ja) 2009-12-16
CA2165458C (fr) 2011-05-10
WO1994029446A3 (fr) 1995-02-02
ES2191031T3 (es) 2003-09-01
FR2706486A1 (fr) 1994-12-23
NZ268038A (en) 1997-12-19
BR9407512A (pt) 1997-01-07
PL312213A1 (en) 1996-04-01
FR2706486B1 (fr) 1995-09-01
KR100342233B1 (ko) 2002-12-05
FI120311B (fi) 2009-09-15
HU219138B (hu) 2001-02-28
CZ329595A3 (en) 1996-03-13
HU9503615D0 (en) 1996-02-28
DE69432075D1 (de) 2003-03-06
CN1126491A (zh) 1996-07-10
EP0703980A1 (de) 1996-04-03
DE69432075T2 (de) 2003-09-04
AU7076394A (en) 1995-01-03
NO955011L (no) 1995-12-11
CZ289039B6 (cs) 2001-10-17
CN1076052C (zh) 2001-12-12
WO1994029446A2 (fr) 1994-12-22
PL180760B1 (pl) 2001-04-30
NO319466B1 (no) 2005-08-15
FI956057L (fi) 1995-12-15
FI956057A0 (fi) 1995-12-15

Similar Documents

Publication Publication Date Title
ATE231916T1 (de) Intrazellulaere bindungs proteine und deren anwendungen
ATE400651T1 (de) Verwendung von grünem fluoreszenzprotein
DE69404835D1 (de) Triesters von phosphorothioaten oligonukleotiden und verfahren zur herstellung
ATE348175T1 (de) Method eder intrazellularen bindung von zielgerichteten molekülen
DE69333731D1 (de) Glialmitogene faktoren, ihre herstellung und verwendung
DE69638032D1 (de) Modifiziertes bacillus thuringiensis gen zur kontrolle von lepidoptera in pflanzen
AU2894289A (en) Domain-modified constant region antibodies
EP0657534A4 (de) Antiallergisches agen.
DE69638142D1 (de) Regulierte Gene und ihre Verwendungen
DE69836823D1 (de) Jmy, mit-aktivator für p300/cbp, dafür kodierendenucleinsäure und deren verwendungen
DE69328549D1 (de) Für einen humanen serotoninrezeptor (5-ht4b) kodierende dns und ihre verwendung
HUT77029A (hu) A GAP-protein SH3 doménjéhez kötődni képes peptidek, ezeket kódoló nukleotidszekvenciák és előállításuk és alkalmazásuk
AU669149B2 (en) Expression signal-peptide-free staphylokinases
ATE317021T1 (de) Antisense modulierung von lfa-3
DK0788549T3 (da) Regulerende nukleinsyresekvenser og anvendelser
ATE423211T1 (de) Produktion von proteinen, dafür kodierende plasmide und organismen, die solche plasmide enthalten
AU7407696A (en) Protein which binds ATP and nucleic acid and which possesses putative helicase and ATPase properties
ATE328088T1 (de) Transketolase-verwandtes protein
DE59611005D1 (de) Mutant des inhibitors des erythrina caffra typs und dessen verwendung zur reinigung von serinproteasen
DE69836226D1 (de) Ifn rezeptor 1 bindende proteine, dafür kodierende dna und verfahren zur regulierung der zellulären antwort auf interferone
Franěk Spontaneous apoptosis contributes negatively to the regulation of hybridoma cell viability

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0703980

Country of ref document: EP